drugset / Trial / NCT01310881

Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

NCT01310881 ↗

Phase 1 Completed 35 enrolled Neuralstem Inc.
RandomizedSingle-groupQuadruple-blindTreatment

Summary

This is a subject single blinded, randomized, placebo-controlled, single dose, first-time-in-human study with three or more ascending cohorts.

Timeline

Start
2011-02
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject NSI-189 Small molecule — Oral

Indications